Bliss GVS Pharma Limited (BLISSGVS.BO)
Bliss GVS Pharma Limited operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Mumbai, MA, IN. The stock last traded at $524.05, up 2.23% on the session, giving a market capitalisation of $55.86B. Its beta of 1.13 implies it has historically moved more than the broad market.
Bliss GVS Pharma Limited, founded in 1984 and based in Mumbai, India, operates as a pharmaceutical enterprise focused on the development, production, and commercialization of a vast array of medicinal formulations and general healthcare items. Its comprehensive pharmaceutical offerings span numerous dosage forms, such as capsules, tablets, injections, oral suspensions, topical creams/gels/ointments, effervescent tablets, eye/ear drops, transdermal patches, and parenterals. In addition to prescription pharmaceuticals, the company manufactures a wide selection of over-the-counter (OTC) and personal care products, including balms, lotions, shampoos, soaps, nasal inhalers, and various sprays and solutions. Addressing a broad spectrum of medical conditions, Bliss GVS's therapeutic catalogue features anti-infectives (e.g., antibacterial, anti-malarial, anti-fungal), anti-inflammatory agents, analgesics, gastrointestinal treatments (such as anti-ulcer and anti-diarrheal medications), anti-diabetics, respiratory support products (like antitussives and nasal decongestants), and an extensive range of nutritional, dermatological, and general wellness supplements, including vitamins, body supplements, and specialized hygiene solutions. The company's products are also distributed internationally through its export operations.
Bliss GVS Pharma Limited is most often compared with the following Healthcare names: